Rallybio Corporation
RLYB
Rank in Stocks
#20449
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to... Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Share Price
$15.66
Last synced: 2026-11-09
Market Cap
$84.31M
Change (1 day)
-0.57%
Change (1 year)
180.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rallybio Corporation (RLYB)
Category
Healthcare
Operating Margin for Rallybio Corporation (RLYB)
Operating Margin as of November 2026 TTM: -4,659.22%
According to Rallybio Corporation's latest financial reports, its current operating margin (TTM) is -4,659.22%. At the end of 2025 the company had an operating margin of -3,270.86%.
Operating Margin history for Rallybio Corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -4,659.22% | 42.45% |
| 2025 | -3,270.86% | -65.61% |
| 2024 | -9,511.95% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.97% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 31.23% | -100.01% |
BE
|
|
| 29.35% | -100.01% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Rallybio Corporation's operating margin
What is Rallybio Corporation's operating margin?
Rallybio Corporation's operating margin is -4,659.22%, as of Nov 2026.
What was Rallybio Corporation's operating margin in 2025?
In 2025, Rallybio Corporation's operating margin was -3,270.86%, compared with -9,511.95% in 2024.
How has Rallybio Corporation's operating margin changed since 2020?
From 2020 to 2025, Rallybio Corporation's operating margin was highest in 2023 (0.00%) and lowest in 2024 (-9,511.95%).
How does Rallybio Corporation's operating margin compare with similar companies?
Rallybio Corporation's operating margin (-4,659.22%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.